MCL1 and diffuse large B-cell lymphoma: Other MCL-1 inhibitors, including PRT1419 (NCT04543305, NCT05107856), MIK665 (as single drug: NCT02992483, terminated, in combination with a BCL2 inhibitor, VOB560: NCT04702425) and AMG 397 (NCT03465540), had also been evaluated in Phase I studies for the treatment of hematological carcinoma including DLBCL.